Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors. A retrospective analysis of 234 cases from the LYSA
| Autor: | Alain Monnereau, Yann Guillermin, Ghandi Damaj, T. Marchand, Xavier Troussard, Delphine Rossille, Gilles Salles, Pascal Godmer, Florence Broussais-Guillaumot, S. Le Gouill, Richard Lemal, Marc Maynadié, Catherine Thieblemont, Thierry Lamy, Adrien Trebouet, Emmanuel Gyan, Christophe Fruchart, Roch Houot, Hélène Monjanel, P. Feugier |
|---|---|
| Přispěvatelé: | Microenvironnement et cancer ( MiCa ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Service d'hématologie, CHU Clermont-Ferrand-Université d'Auvergne - Clermont-Ferrand I ( UdA ), CIC - Clermont Ferrand, Institut National de la Santé et de la Recherche Médicale ( INSERM ), CHRU Tours, CIC - Tours, CHRU Tours-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut Paoli Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre Léon Bérard [Lyon], Gvh et Gvl : Physiopathologie Chez l'Homme et Chez l'Animal, Incidence et Role Therapeutique, Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service d'hématologie [Hôpital Edouard Herriot - HCL], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), Centre hospitalier universitaire de Nantes ( CHU Nantes ), Centre Hospitalier de Bretagne Atlantique, Centre François Baclesse, Centre hospitalier universitaire d'Amiens ( CHU Amiens-Picardie ), CHU Amiens-Picardie, Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Centre d'épidémiologie des populations ( CEP ), Université de Bourgogne ( UB ) -Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ), Département d'oncologie médicale, Institut Bergonié - CRLCC Bordeaux, CHU Caen, Pôle Biologie, Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Microenvironnement et cancer (MiCa), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Clermont-Ferrand-Université d'Auvergne - Clermont-Ferrand I (UdA), Centre d'Investigation Clinique [CHU Clermont-Ferrand] (CIC 1405), Institut National de la Santé et de la Recherche Médicale (INSERM)-Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Paoli-Calmettes, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre hospitalier Bretagne Atlantique (Morbihan) (CHBA), Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre d'épidémiologie des populations (CEP), Université de Bourgogne (UB)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER, Institut Bergonié [Bordeaux], Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Martin, Clémence, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU) |
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Male
medicine.medical_specialty Palliative care Survival Population [SDV.CAN]Life Sciences [q-bio]/Cancer lymphoma [ SDV.CAN ] Life Sciences [q-bio]/Cancer 03 medical and health sciences 0302 clinical medicine [SDV.CAN] Life Sciences [q-bio]/Cancer immune system diseases Internal medicine hemic and lymphatic diseases Antineoplastic Combined Chemotherapy Protocols medicine Humans Hypoalbuminemia education Serum Albumin 030304 developmental biology Cause of death Retrospective Studies Aged 80 and over 0303 health sciences education.field_of_study palliative care business.industry Incidence (epidemiology) Incidence Lymphoma Non-Hodgkin Hematology medicine.disease Prognosis Comorbidity 3. Good health Lymphoma Surgery aged 80 and over comorbidity Oncology 030220 oncology & carcinogenesis Female Lymphoma Large B-Cell Diffuse business Diffuse large B-cell lymphoma |
| Zdroj: | Annals of Oncology Annals of Oncology, Oxford University Press (OUP), 2013, 24 (10), pp.2612-8. 〈10.1093/annonc/mdt282〉 Annals of Oncology, 2013, 24 (10), pp.2612-8. ⟨10.1093/annonc/mdt282⟩ Annals of Oncology, Elsevier, 2013, 24 (10), pp.2612-8. ⟨10.1093/annonc/mdt282⟩ |
| ISSN: | 0923-7534 1569-8041 |
| Popis: | International audience; BACKGROUND: Lymphoma occurring in patients aged 90 or older is not uncommon, and its incidence is expected to increase over time. Management of these patients is difficult given their underlying fragility and the lack of information regarding this population. PATIENTS AND METHODS: We retrospectively analyzed 234 patients diagnosed with lymphoma at the age of 90 years or older (90+) between 1990 and 2012 to describe their characteristics, management, outcomes and prognostic factors. RESULTS: The median age was 92 years; 88% were B-cell lymphomas consisting mainly in diffuse large B-cell lymphoma. The median overall survival (OS) was 7.2 months (range, 0-92 months) for the 227 patients with non-Hodgkin Lymphoma (NHL), with a significant difference between aggressive and indolent NHL (5.2 months versus 19.4 months, respectively). We further analyzed 166 NHL patients for whom detailed characteristics were available. Among these patients, 63.5% received a treatment, either local (7.5%) or systemic (56%). Lymphoma was reported as the main cause of death (40%). Treatment administration was associated with improved OS in patients with aggressive (P < 0.001) but not indolent NHL (P = 0.96). In patients with aggressive NHL, hypoalbuminemia appeared as a strong and independent negative prognostic factor. CONCLUSIONS: The median OS is short in 90+ patients diagnosed with lymphoma but some patients experience prolonged survival. Lymphoma represents the main cause of death in these patients. Treatment may improve survival of selected patients with aggressive but not indolent NHL. Management of these patients may be guided by prognostic factors identified in this study, notably serum albumin. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|